Using Pentoxifylline to Reduce Complications After Breast Cancer Surgery
The Efficacy of Pentoxifylline in Reducing Post-surgical Complications in Patients Undergoing Breast Cancer Surgery
This study is testing if taking pentoxifylline before and after breast cancer surgery can help patients heal better and feel less pain compared to those who take a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | Mansoura University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Mansoura) |
| Trial ID | NCT06087237 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of pentoxifylline in minimizing post-surgical complications in breast cancer patients undergoing mastectomy. Participants will receive oral pentoxifylline before and after surgery, while a control group will receive a placebo. The study aims to compare pain scores and wound healing times between the two groups over a period of two weeks. The goal is to determine if pentoxifylline can significantly improve recovery outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates are adult female patients aged 18 to 65 who have completed neoadjuvant chemotherapy and are scheduled for breast cancer surgery.
Not a fit: Patients currently on phosphodiesterase inhibitors, antiplatelet or anticoagulant treatments, or those with certain medical histories may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could lead to reduced pain and faster wound healing for breast cancer surgery patients.
How similar studies have performed: While pentoxifylline has been studied in various contexts, this specific application in breast cancer surgery is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult female patients aged 18 to 65 years 2. Patients completed neoadjuvant chemotherapy cycles and scheduled for breast cancer surgery. Exclusion Criteria: 1. Patients on treatment regimen of phosphodiesterase inhibitors 2. Patients who are taking antiplatelet or anticoagulant treatment 3. Patients who are allergic to phosphodiesterase inhibitors 4. History of recent hemorrhagic events 5. Active peptic ulcer 6. History of psychological problems 7. History of chronic pain management 8. Pregnancy or breastfeeding
Where this trial is running
Mansoura
- Oncology center of Mansoura University — Mansoura, Egypt (Recruiting)
Study contacts
- Principal investigator: Omar H. Abdelaleem, PhD — Faculty pf medicine, Mansoura University
- Study coordinator: Samar A. Dewidar, MSc
- Email: s.dewidar@mans.edu.eg
- Phone: +201558333468
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.